Newsroom

DARMSTADT, Germany & BIBLIS, Germany--(BUSINESS WIRE)--Following its successful USD 240 million financing round, Focused Energy is continuing to systematically advance the industrialization of laser fusion as its core business. At the same time, the company plans to consolidate its activities in the field of laser-driven radiation sources into an independent entity under the name Sourcelight. With this move, Focused Energy is laying the groundwork for the industrial transfer of selected technol...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust US Momentum UCITS ETF 09.06.2026 FTMO.LN IE000CY30YV9 3,050,002.00 USD 91,604,717.24 30.034  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust SMID Rising Dividend Achievers UCITS ETF 09.06.2026 SDVI.LN IE000YVOQ2A3 40,361.00 USD 1,144,826.52 28.365  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust SMID Rising Dividend Achievers UCITS ETF 09.06.2026 SDVY.LN IE0001R850E1 14,604,007.00 USD 364,891,574.74 24.986  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Growth Strength UCITS ETF 09.06.2026 FTGS.LN IE000YZLMXT9 25,002.00 USD 577,217.77 23.087  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Moderate Buffer UCITS ETF - February 09.06.2026 GFEB.LN IE000X8M8M80 700,002.00 USD 27,241,372.34 38.916  ...

CAMBRIDGE, England--(BUSINESS WIRE)--PhoreMost Limited (“PhoreMost”), a biotech company focused on turning scientific breakthroughs into life-changing cancer drugs, today announced its lead programme, PMC-001, a next-generation, small molecule microtubule targeting agent (MTA) for primary and secondary brain cancers. The milestone marks the Company’s progress towards first-in-human clinical trials, with a pipeline of differentiated and first-in-class assets in oncology. PMC-001 is a highly diff...

LJUBLJANA, Slovenia--(BUSINESS WIRE)--Cosylab and Heron Neutron Medical Corp. announced today, 10 June 2026, the signing of a Letter of Intent to establish a strategic framework for joint market development to support the global deployment of Accelerator-Based Boron Neutron Capture Therapy (AB-BNCT) systems. The collaboration aims to accelerate the development and integration of sophisticated software solutions for use with AB-BNCT while strengthening AB-BNCT's international market access and b...

LONDON--(BUSINESS WIRE)--Laverock Therapeutics (‘Laverock’), a biotechnology company developing disease-responsive advanced therapies through its unique, programmable gene control technology, today announced key in-vivo functional milestones across its T-cell and macrophage oncology programmes for solid tumour indications. The data support lead programme selection and progression towards the clinic. Laverock’s platform technology enables programmable, tunable and multiplex gene control for both...

DRESDEN, Duitsland & DELFT, Nederland--(BUSINESS WIRE)--GlobalFoundries and Qualinx Demonstrate First European Sovereign Manufacturing Flow for Security‑Critical Semiconductors...